Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Friday, September 12, according to the funds’ daily disclosures. The ace hedge fund manager added to five names spanning tech, fintech, and biotech, including Figma (FIG) and Bullish (BLSH), while scaling back her position in Tempus AI (TEM).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The ARK Genomic Revolution ETF (ARKG) sold 2,636 shares of Tempus AI worth $234,024, continuing its gradual pullback from the AI-driven health-tech company. This followed a larger trim earlier on Friday, when the fund offloaded 58,629 shares valued at $4.6 million.
Wood Continues to Load Up on Figma and BLSH
The biggest buy came from the ARK Next Generation Internet ETF (ARKW), which bought 151,501 shares of Figma valued at $8.48 million. The purchase shows ARK’s growing interest in the creative software space. Figma is known for its collaborative design tools that continue to disrupt the traditional software market. The company debuted on the New York Stock Exchange on July 31 at $33 per share.
Meanwhile, the ARK Fintech Innovation fund (ARKF) added 45,037 shares of newly listed company, Bullish, for about $2.43 million. This continues a pattern of steady buying, signaling strong conviction in the digital currency exchange platform.
Wood Expands Bets across Sectors
ARKF also purchased 33,710 shares of eToro Group (ETOR), valued at $1.50 million. The social trading network has gained attention for its easy-to-use platform that lets users invest across multiple asset classes.
Meanwhile, ARKF picked up 36,685 shares of Toast (TOST), a restaurant software provider, for $1.50 million. Toast offers cloud-based tools that help restaurants manage operations more efficiently.
At the same time, ARKG added 25,710 shares of Arcturus Therapeutics (ARCT) for $463,808. The biotech firm develops RNA-based medicines.
Here’s how these stocks perform on TipRanks’ Stock Comparison Tool:
